About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Los Angeles | 16,901 Studies Near You | Clareo Health

Clinical Trials LocationsLos Angeles

Clinical Trials in Los Angeles

Discover 16,901 clinical trials near Los Angeles, California. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 3641-3660 of 16,901 trials

RECRUITINGPhase 1< 1 mile

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

NCT05808634

The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma

Advanced Adenocarcinoma

BioAtla, Inc.168 participantsStarted Jul 2023

Irvine, California, United States • Los Angeles, California, United States • New Haven, Connecticut, United States +6 more locations

COMPLETEDPhase 2< 1 mile

ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder

NCT05749055

The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)

Generalized Anxiety Disorder

Engrail Therapeutics INC252 participantsStarted Jul 2023

Phoenix, Arizona, United States • Garden Grove, California, United States • Imperial, California, United States +29 more locations

Find Trials by Condition in Los Angeles

Breast Cancerin Los Angeles Lung Cancerin Los Angeles Prostate Cancerin Los Angeles Colorectal Cancerin Los Angeles Melanomain Los Angeles Leukemiain Los Angeles Lymphomain Los Angeles Pancreatic Cancerin Los Angeles Ovarian Cancerin Los Angeles Brain Cancerin Los Angeles

Data from ClinicalTrials.govTerms

RECRUITINGPhase 1< 1 mile

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

NCT06501196

Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS). Phase 1, Part 1 Dose Escalation - Monotherapy will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of BH-30236 administered orally. Approximately 50 participants may be enrolled in Phase 1, Part 1 Dose Escalation - Monotherapy. Phase 1, Part 2 Dose Escalation - Combination with Venetoclax will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of BH-30236 administered as a combination therapy with venetoclax. Approximately 48 participants may be enrolled in Phase 1, Part 2 Dose Escalation - Combination with Venetoclax. Phase 1b (Dose Expansion) will follow Phase 1 to further understand the relationships among dose, exposure, toxicity, tolerability, and clinical activity. Up to 72 participants may be enrolled in Phase 1b of the study as a monotherapy or in combination with venetoclax.

LeukemiaLeukemia, MyeloidLeukemia, Myeloid, Acute+3 more

BlossomHill Therapeutics170 participantsStarted Jun 2024

Duarte, California, United States • Los Angeles, California, United States • Palo Alto, California, United States +10 more locations

COMPLETEDPhase 3< 1 mile

A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis

NCT05587309

The objective of the Healing Phase of the study is to evaluate the safety and efficacy of up to 8 weeks of once daily oral administration of BLI5100 versus a PPI control in healing EE. The objective of the Maintenance Phase of the study is to evaluate the safety and efficacy of 24 weeks of once daily oral administration of BLI5100 (low or high dose) versus a PPI control in the maintenance of healed EE.

Erosive Esophagitis

Braintree Laboratories1,250 participantsStarted Oct 2022

Homewood, Alabama, United States • Huntsville, Alabama, United States • Peoria, Arizona, United States +119 more locations

RECRUITINGNA< 1 mile

Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants

NCT05380401

A comprehensive analysis of the impact of exogenous enteral DHA and ARA supplementation on lipid metabolism including the production of downstream derived mediators and how this impacts important biological pathways such as metabolism, inflammation, and organogenic factors.

The University of Texas Health Science Center at San Antonio328 participantsStarted Mar 2023

Los Angeles, California, United States • New Haven, Connecticut, United States • Chicago, Illinois, United States +4 more locations

Active Not RecruitingPhase 16.3 miles

A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

NCT05485974

A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.

Lung CancerNon Small Cell Lung CancerColorectal Cancer+4 more

HUYABIO International, LLC.44 participantsStarted Aug 2022

Encinitas, California, United States • Glendale, California, United States • Long Beach, California, United States +11 more locations

Active Not RecruitingPhase 36.3 miles

A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

NCT05456425

The objective is to evaluate the safety and efficacy of low dose and high dose CBT-001 eye drop dosed twice daily for 24 months compared to vehicle in reducing conjunctival hyperemia and preventing pterygium progression in eyes with pterygia.

Cloudbreak Therapeutics, LLC660 participantsStarted Jun 2022

Dothan, Alabama, United States • Sun City, Arizona, United States • Bakersfield, California, United States +41 more locations

RECRUITINGPhase 16.3 miles

A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia

NCT06859073

This study will evaluate an investigational drug called NNC4004-0002. "Investigational" means NNC4004-0002 has not been approved for sale/ for clinical use or for the use described in this study/ by any regulatory authority. Its use in this study is experimental. This will be the first time that NNC4004-0002 will be given to human. This study will be testing the ability of the study medicine to lower serum uric acid. The main aim of this study will be to see if the new study medicine is safe and tolerated by the body after a single dose of study medicine in adults with asymptomatic hyperuricemia. Participants will either get NNC4004-0002 (the study medicine), or saline. Which treatment the participant get will be decided by chance. The participant will get the medicine as an injection under their skin. Depending on the dose they will receive, participant may need more than one injection. The study will last for about 19 months in total. The participant will take part in the study for about 7 months. Participant will have approximately 14 visits to the clinic and one of them will be a 4 night in-house stay.

Healthy VolunteersHyperuricemia

Novo Nordisk A/S60 participantsStarted Nov 2024

Glendale, California, United States • Baltimore, Maryland, United States

COMPLETEDPhase 29.1 miles

A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

NCT05737940

This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2

Pulmonary Hypertension (World Health Organization Group 2)Heart Failure

AstraZeneca260 participantsStarted Apr 2023

Beverly Hills, California, United States • La Jolla, California, United States • New Haven, Connecticut, United States +57 more locations

Active Not RecruitingPhase 114 miles

A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

NCT05163028

A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and recommended Phase II dose of HBI-2376 and characterize its pharmacokinetic profile.

Non Small Cell Lung CancerColorectal CancerPancreatic Cancer+4 more

HUYABIO International, LLC.42 participantsStarted Dec 2021

Duarte, California, United States • Encinitas, California, United States • Fullerton, California, United States +9 more locations

COMPLETEDPhase 316 miles

A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery

NCT05425056

The primary study objective is to evaluate the benefit of the Sirolimus eluting Collagen implant (SeCI; Sirogen), a single dose prophylactic treatment delivered intraoperatively at the time of surgical creation of an arteriovenous fistula for hemodialysis vascular access.

Complication of Renal DialysisEnd Stage Renal DiseaseEnd Stage Kidney Disease+5 more

Vascular Therapies, Inc.136 participantsStarted Aug 2022

San Diego, California, United States • Torrance, California, United States • Washington D.C., District of Columbia, United States +19 more locations

RECRUITINGPhase 216 miles

Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

NCT04561206

This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Nivolumab is an antibody that enhances the immune system to better fight Hodgkin lymphoma cells. Giving brentuximab vedotin and nivolumab may be able to defer stem cell transplant treatment and spare the considerable cost and toxicity on transplantation.

Relapsed Classic Hodgkin Lymphoma

City of Hope Medical Center31 participantsStarted Nov 2021

Duarte, California, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States +2 more locations

Active Not RecruitingPhase 229 miles

Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ

NCT03935685

The purpose of the study is to estimate the ability of mirtazapine to reduce depression, nausea, and vomiting, and maintain weight in depressed glioma patients undergoing Temozolomide (TMZ) therapy. Of equal importance, the investigators will monitor the tolerability of Mirtazapine in these patients over the course of the study.

Glioma of Brain

University of California, Irvine120 participantsStarted Feb 2019

Orange, California, United States

COMPLETEDNA35 miles

Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes

NCT06273124

The purpose of this study is to collect clinical data to support a 7-day wear of the Extended Wear Infusion Set (EWIS). Participants will be asked to: 1. Wear the EWIS for up to 7 consecutive days for 12 consecutive wear periods 2. Perform blood glucose and ketone measurements if continuous glucose meter is ≥250mg/dL for one hour

Tandem Diabetes Care, Inc.260 participantsStarted Mar 2024

Newport Beach, California, United States • Stanford, California, United States • Aurora, Colorado, United States +12 more locations

COMPLETEDNA36 miles

Effects of Voluntary Adjustments During Walking in Participants Post-stroke

NCT06034119

People post-stroke retain the capacity to modify walking patterns explicitly using biofeedback and implicitly when encountering changes in the walking environment. This proposal will assess changes in muscle activation patterns associated with walking modifications driven explicitly vs. implicitly, to determine whether individuals generate different amounts of co-contraction during explicit vs. implicit walking modifications. Understanding how walking modifications driven explicitly vs. implicitly influence co-contraction will allow the investigators to identify approaches that can more effectively restore muscle activation toward pre-stroke patterns, promoting mechanism-based recovery of walking function.

Chapman University44 participantsStarted Sep 2023

Irvine, California, United States

Active Not RecruitingPhase 277 miles

A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

NCT06284954

This study will evaluate the safety and efficacy of empasiprubart compared with placebo in adult participants with dermatomyositis (DM). The study duration will be approximately 92 weeks for all participants. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive either empasiprubart or placebo, respectively, during the treatment period (duration of 25 weeks). At the end of the treatment period, all the participants will enter a safety follow-up period (duration of 65 weeks).

DermatomyositisMyositis

argenx3 participantsStarted Aug 2024

Oceanside, California, United States • DeBary, Florida, United States • Gainesville, Florida, United States +25 more locations

COMPLETEDPhase 2113 miles

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

NCT05239468

Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (OCA) in participants with Primary Biliary Cholangitis (PBC).

Primary Biliary Cholangitis

Intercept Pharmaceuticals72 participantsStarted Mar 2022

Birmingham, Alabama, United States • Coronado, California, United States • Mission Hills, California, United States +23 more locations

COMPLETEDPhase 3229 miles

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

NCT03367572

This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron hydrochloride and dexamethasone in improving chemotherapy-induced nausea and vomiting in patients with breast cancer. Antiemetic drugs, such as prochlorperazine and olanzapine, may help lessen nausea and vomiting in patients with breast cancer treated with chemotherapy.

Breast Carcinoma

University of Rochester NCORP Research Base1,363 participantsStarted Apr 2018

Honolulu, Hawaii, United States • Decatur, Illinois, United States • New Orleans, Louisiana, United States +15 more locations

COMPLETEDPhase 2320 miles

Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion

NCT02070744

The objective of this study was to evaluate the safety and efficacy of VX-661in combination with ivacaftor in participants with cystic fibrosis (CF) who are homozygous for F508del cystic fibrosis transmembrane conductance regulator (CFTR) mutation

Cystic Fibrosis

Vertex Pharmaceuticals Incorporated40 participantsStarted Mar 2014

Birmingham, Alabama, United States • Palo Alto, California, United States • Stanford, California, United States +20 more locations

RECRUITING826 miles

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

NCT03739827

Background: Approximately 150 cases of cancer per one million per year are considered rare cancers. While all tumors originate from genetic changes, a small percentage of these tumors are familial. Researchers want to study these changes in biological samples from people with rare tumors in order to learn more about how these tumors develop. The information obtained from this study may lead to improved screening, preventive guidelines, and treatments. Objective: To better understand rare cancers and hereditary cancer syndromes. Eligibility: People who have a rare tumor, a family history of a rare tumor, a hereditary cancer syndrome, or a mutation that leads to rare tumors. Design: Participants will be screened with questions about their medical history and/or that of their family members. They will give a saliva sample. Participants who have a tumor will have their medical records and tests reviewed. They will answer questions about their wellbeing and needs. They may provide a tumor tissue sample. Participants may also have: * Physical exam * Clinical photography * Blood, urine, saliva, and stool samples taken * Consultation with specialists * A scan that produces a picture of the body. Either one that uses a small amount of radiation, or one that uses a magnetic field. * Genetic testing/genetic counseling. Participants will be contacted once a year. They will answer updated questions about their medical and family history. Participants will be asked to contact the study team if there are changes in their tumors. Participants may be invited to join focus groups for people with the same diagnosis of rare tumors. Participants may be invited to participate in other NIH protocols. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* RARE TUMOR LIST: 1. Acinar cell carcinoma of the pancreas 2. Adamantinoma 3. Adenosqaumous carcinoma of the pancreas 4. Adrenocortical carcinoma 5. Alveolar soft part sarcoma 6. Anaplastic Thyroid Cancer 7. Angiosarcoma 8. Atypical Teratoid Rhabdoid Tumor/MRT 9. Carcinoid 10. Carcinoma of Unknown Primary 11. Chondrosarcoma 12. Chondromyxoid fibroma 13. Chordoma 14. Clear cell renal carcinoma 15. Clear Cell Sarcoma 16. Clear cell sarcoma of kidney 17. Conventional chordoma 18. Dedifferentiated chordoma 19. Desmoid 20. Desmoplastic small round cell tumor 21. Epithelioid hemangioendothelioma 22. Esthenioneuroblastoma 23. Ewing Sarcoma 24. Fibrolamellar carcinoma 25. Fusion negative rhabdomyosarcoma 26. Fusion positive renal cell carcinoma 27. Fusion positive rhabdomyosarcoma 28. Gastro-enteropancreatic neuroendocrine tumor 29. Hepatoblastoma 30. Hereditary Diffuse Gastric Cancer 31. Inflammatory myofibroblastic tumor 32. Kaposiform hemangioendothelioma 33. Malignant ectomesenchymal tumor 34. Malignant peripheral nerve sheath tumor 35. Malignant triton tumor 36. Medullary thyroid cancer 37. Mixed acinar adenocarcinoma 38. Mixed acinar neuroendocrine carcinoma 39. Myxoid Liposarcoma 40. Neuroblastoma 41. Neuroendocrine tumors 42. NUT midline carcinoma 43. Osteosarcoma 44. Pancreas ductal adenocarcinoma with squamous features 45. Pancreatic acinar cell carcinoma 46. Papillary renal cell carcinoma 47. Paraganglioma 48. Parosteal Osteosarcoma 49. Periosteal Osteosarcoma 50. Peripheral nerve sheath tumor 51. Peripheral primitive neuroectodermal tumor 52. Pheochromocytoma 53. Pituitary cancer 54. Poorly differentiated chordoma 55. Renal medullary carcinoma 56. Rhabdomyosarcoma 57. Round cell Liposarcoma 58. Schwannoma 59. Sclerosing Epithelioid Fibrosarcoma 60. SDH deficient GIST 61. SMARCB1 deficient tumors 62. SMARCA4 deficient tumors 63. Synovial sarcoma 64. Undifferentiated Sarcoma \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Malignant Solid TumorsOther Neoplasms Solid TumorsPediatric Solid Tumor+2 more

National Cancer Institute (NCI)10,000 participantsStarted Jan 2019

Bethesda, Maryland, United States • Portland, Oregon, United States • Houston, Texas, United States

PreviousPage 183 of 846Next

Diabetes

in Los Angeles

Heart Diseasein Los Angeles